Our vision is
To apply life science and technology precisely in clinical treatment
To locate the origin of cancers
To adhere the basis of human science
To benefit those in need
At OrigiMed, a leading precision medicine company, we are devoted to providing the most high quality comprehensive molecular diagnostic technology to assist in personalized treatments for patients and physicians. Advanced and customized ‘one-stop’ solutions from OrigiMed have supported pharmaceutical companies in the development of trials, treatments and companion diagnostic kits. Our aim is to promote further innovative reformation in cancer management in China.
more >
NGS test combing
DNA and RNA
sequencing in China
Internet Hospital
focusing on
precision medicine in China
company on precision medicine
that conducted comparative
studies with FDA-approved
comprehensive gene panel tests in China
NGS based companion diagnostic
product for NTRK gene fusion
detection in China
Chinese company on precision medicine
that published studies based on
Chinese specific populations in
well-known academic journal Cell
company on precision medicine
that made international publications on
utility validation of NGS products
of complete sequencing assays in China
Covering over 50 types of solid tumors and hematologic neoplasms.
The first NGS test combing DNA and RNA sequencing in China.
High-quality publications based on real-world studies.
Central laboratory at international standards.
Growing experience in new drug R&D and companion diagnostic solutions.
Explore in biomarker discovery.
OrigiMed-only system of real-world studies.
The first internet hospital focusing on precision medicine in China.
International molecular pathological platform.
Multiple Disciplinary Team (MDT).
International Molecular Tumor Board (MTB).
OrigiMed Co., Ltd.(“OrigiMed”) announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. (“Janssen”).
SHANGHAI, Aug. 22, 2021 /PRNewswire/ -- OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing Kit has been granted the Special Review Procedure for Innovative Medical Devices by the Center for Medical Device Evaluation of NMPA.
The collaboration will develop an innovative genomic-based clinical treatment platform